Compare ZCMD & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZCMD | CLDI |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | China | United States |
| Employees | N/A | 29 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.4M |
| IPO Year | 2019 | N/A |
| Metric | ZCMD | CLDI |
|---|---|---|
| Price | $1.10 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.7M | 1.9M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.09 |
| 52 Week High | $11.96 | $6.06 |
| Indicator | ZCMD | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 89.20 |
| Support Level | $0.75 | $1.17 |
| Resistance Level | $2.70 | N/A |
| Average True Range (ATR) | 1.14 | 0.09 |
| MACD | -0.10 | 0.20 |
| Stochastic Oscillator | 0.73 | 90.75 |
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.